RSS-Feed abonnieren
PDF herunterladen
DOI: 10.4103/ijmpo.ijmpo_42_16
Pediatric Nonblastic Non-Hodgkin’s Lymphoma: A Perspective from India
Financial support and sponsorship Nil.
Abstract
Background: There is a paucity of data on pediatric nonblastic non-Hodgkin's lymphoma (NHL) from developing countries. We conducted this study to study outcome and identify risk factors that can predict survival in pediatric nonblastic NHL at our center. Methods: Patients <18 years of age who were diagnosed with nonlymphoblastic NHL at our hospital from January 1, 2005, to December 31, 2014, were included. Data were collected retrospectively from case records. Results: One hundred and two patients with median age of 12 years (range: 1–18) were included in the study. There were 69/102 (68%) male and 33/102 (32%) female patients. The most common histological diagnosis was Burkitt's lymphoma (BL) in 59/102 (58%) patients followed by anaplastic large cell lymphoma (ALCL) in 28/102 (28%) patients and diffuse large B-cell lymphoma (DLBCL) in 12/102 (12%) patients, T-cell lymphoma in 2/102 patients, and primary mediastinal B-cell lymphoma in 1/102 patients. The LMB-89 protocol was the most common protocol used for treatment in 74/102 (72%) patients. The 2-year event-free survival (EFS) for patients with BL, ALCL, and DLBCL was 72%, 55.8%, and 27.5%, respectively (P = 0.037). On univariate analysis, factors that significantly predicted poor EFS included non-BL histological subtype, poor performance status, malnutrition, use of less intense chemotherapy, and not achieving complete response on interim radiological assessment. Conclusions: Outcomes in nonblastic NHL from our center are worse compared to data from the west. This is because a large proportion of patients present with advanced stage and in moribund condition. Patients with BL have better outcome compared to other subtypes.
Publikationsverlauf
Artikel online veröffentlicht:
23. Juni 2021
© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D. et al. The Société Française D'oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370-9
- 2 Advani S, Pai S, Adde M, Vaidya S, Vats T, Naresh K. et al. Preliminary report of an intensified, short duration chemotherapy protocol for the treatment of pediatric non-Hodgkin's lymphoma in India. Ann Oncol 1997; 8: 893-7
- 3 Murphy SB, Fairclough DL, Hutchison RE, Berard CW. Non-Hodgkin's lymphomas of childhood: An analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989; 7: 186-93
- 4 Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G. et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 2001; 97: 3699-706
- 5 Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602
- 6 WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development. Geneva: World Health Organization; 2006.
- 7 Ahmad N, Zaidi A, Badar F, Maaz AU, Akram MS. Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia Pac J Clin Oncol 2010; 6: 49-56
- 8 Moleti ML, Al-Hadad SA, Al-Jadiry MF, Al-Darraji AF, Al-Saeed RM, De VellisA. et al. Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country. Pediatr Blood Cancer 2011; 56: 560-7
- 9 Bakhshi S, Radhakrishnan V, Sharma P, Kumar R, Vishnubhatla S. et al. Pediatric nonlymphoblastic non-Hodgkin lymphoma: Baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation – A prospective study. Radiology 2012; 262: 956-68
- 10 Lakshmaiah KC, Guruprasad B, Shah A, Kavitha S, Abraham LJ, Govindbabu K. et al. Anaplastic large cell lymphoma: A single institution experience from India. J Cancer Res Ther 2013; 9: 649-52
- 11 Manipadam MT, Nair S, Viswabandya A, Mathew L, Srivastava A, Chandy M. et al. Non-Hodgkin lymphoma in childhood and adolescence: Frequency and distribution of immunomorphological types from a tertiary care center in South India. World J Pediatr 2011; 7: 318-25